Matches in SemOpenAlex for { <https://semopenalex.org/work/W2296017728> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2296017728 endingPage "e15150" @default.
- W2296017728 startingPage "e15150" @default.
- W2296017728 abstract "e15150 Background: Although taxanes represent the most active agents for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC), most patients eventually progress while receiving taxane-based treatments. No agents are currently approved for second-line therapy in HRPC. Methods: Seven patients with HRPC, pre-treated with docetaxel received combination therapy with bevacizumab (15 mg/kg) and docetaxel (60 mg/m2) every 3 weeks. The inclusion criteria were: age >18 years, World Health Organization performance status 0-1, histologically confirmed adenocarcinoma of prostate, metastatic disease shown by either CT scan or bone scan, previous hormonal therapy with LHRH and anti-androgen combined and progression on chemotherapy with docetaxel as first line treatment. Progression was defined as >50% increase in PSA on two determinations in two weeks apart. The response criteria is defined as with measurement of PSA on two separate occasions with two weeks apart as follows: 1) major PSA response was defined as a reduction from baseline of ≥50%, 2) minor response was defined as a ≥25% to 49%, 3) stable disease defined as to a <25% PSA response, 4) progression defined as more than 25% increase. Results: The study was carried out from July 2006 till Dec 2009. The mean age of our patients was 72.3 years (range 51-82 years). The mean duration of combination treatment was 5.4 months (range 2-9 months). Three patients (43%) had major PSA response; three patients (43%) had minor PSA response while one patient (14%) had disease progression on combination therapy. Two partial responders had thrombocytopenia due to which the treatment was discontinued and two patients experienced grade 1-2 anorexia. No evidence of headaches, proteinuria, hematuria or bleeding was observed. Conclusions: Our results show that the combination of bevacizumab and docetaxel is an active regimen in HRPC after failure on treatment with docetaxel. Platelet counts should be monitored during the therapy. These promising results may provide a basis for further research in a large multicenter trial. No significant financial relationships to disclose." @default.
- W2296017728 created "2016-06-24" @default.
- W2296017728 creator A5001377252 @default.
- W2296017728 creator A5005753175 @default.
- W2296017728 creator A5005772570 @default.
- W2296017728 creator A5024485378 @default.
- W2296017728 creator A5041231796 @default.
- W2296017728 creator A5049547009 @default.
- W2296017728 creator A5053188863 @default.
- W2296017728 creator A5060260500 @default.
- W2296017728 creator A5087945532 @default.
- W2296017728 date "2010-05-20" @default.
- W2296017728 modified "2023-09-27" @default.
- W2296017728 title "Efficacy of combined docetaxel and bevacizumab treatment in hormone-refractory metastatic prostate cancer pretreated with docetaxel: A single institution experience." @default.
- W2296017728 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.e15150" @default.
- W2296017728 hasPublicationYear "2010" @default.
- W2296017728 type Work @default.
- W2296017728 sameAs 2296017728 @default.
- W2296017728 citedByCount "0" @default.
- W2296017728 crossrefType "journal-article" @default.
- W2296017728 hasAuthorship W2296017728A5001377252 @default.
- W2296017728 hasAuthorship W2296017728A5005753175 @default.
- W2296017728 hasAuthorship W2296017728A5005772570 @default.
- W2296017728 hasAuthorship W2296017728A5024485378 @default.
- W2296017728 hasAuthorship W2296017728A5041231796 @default.
- W2296017728 hasAuthorship W2296017728A5049547009 @default.
- W2296017728 hasAuthorship W2296017728A5053188863 @default.
- W2296017728 hasAuthorship W2296017728A5060260500 @default.
- W2296017728 hasAuthorship W2296017728A5087945532 @default.
- W2296017728 hasConcept C121608353 @default.
- W2296017728 hasConcept C126322002 @default.
- W2296017728 hasConcept C126894567 @default.
- W2296017728 hasConcept C141071460 @default.
- W2296017728 hasConcept C143998085 @default.
- W2296017728 hasConcept C2775930923 @default.
- W2296017728 hasConcept C2776694085 @default.
- W2296017728 hasConcept C2777511904 @default.
- W2296017728 hasConcept C2777802072 @default.
- W2296017728 hasConcept C2778311097 @default.
- W2296017728 hasConcept C2778822529 @default.
- W2296017728 hasConcept C2780192828 @default.
- W2296017728 hasConcept C2781190966 @default.
- W2296017728 hasConcept C530470458 @default.
- W2296017728 hasConcept C71924100 @default.
- W2296017728 hasConceptScore W2296017728C121608353 @default.
- W2296017728 hasConceptScore W2296017728C126322002 @default.
- W2296017728 hasConceptScore W2296017728C126894567 @default.
- W2296017728 hasConceptScore W2296017728C141071460 @default.
- W2296017728 hasConceptScore W2296017728C143998085 @default.
- W2296017728 hasConceptScore W2296017728C2775930923 @default.
- W2296017728 hasConceptScore W2296017728C2776694085 @default.
- W2296017728 hasConceptScore W2296017728C2777511904 @default.
- W2296017728 hasConceptScore W2296017728C2777802072 @default.
- W2296017728 hasConceptScore W2296017728C2778311097 @default.
- W2296017728 hasConceptScore W2296017728C2778822529 @default.
- W2296017728 hasConceptScore W2296017728C2780192828 @default.
- W2296017728 hasConceptScore W2296017728C2781190966 @default.
- W2296017728 hasConceptScore W2296017728C530470458 @default.
- W2296017728 hasConceptScore W2296017728C71924100 @default.
- W2296017728 hasIssue "15_suppl" @default.
- W2296017728 hasLocation W22960177281 @default.
- W2296017728 hasOpenAccess W2296017728 @default.
- W2296017728 hasPrimaryLocation W22960177281 @default.
- W2296017728 hasRelatedWork W2073443344 @default.
- W2296017728 hasRelatedWork W2147013188 @default.
- W2296017728 hasRelatedWork W2147874203 @default.
- W2296017728 hasRelatedWork W2160411736 @default.
- W2296017728 hasRelatedWork W2328551487 @default.
- W2296017728 hasRelatedWork W2346157159 @default.
- W2296017728 hasRelatedWork W2415167417 @default.
- W2296017728 hasRelatedWork W2468666928 @default.
- W2296017728 hasRelatedWork W2560076969 @default.
- W2296017728 hasRelatedWork W4248552131 @default.
- W2296017728 hasVolume "28" @default.
- W2296017728 isParatext "false" @default.
- W2296017728 isRetracted "false" @default.
- W2296017728 magId "2296017728" @default.
- W2296017728 workType "article" @default.